[{"id":"8071c405-9b54-4ff6-82e5-09e8fad7fb2c","acronym":"T-LGLL","url":"https://clinicaltrials.gov/study/NCT05141682","created_at":"2021-12-02T18:54:30.785Z","updated_at":"2025-02-25T12:38:03.521Z","phase":"Phase 1/2","brief_title":"Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05141682 - T-LGLL","lead_sponsor":"Jonathan Brammer","biomarkers":" CD8","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"862eb385-171b-4581-9e17-fb92dd0e69c0","acronym":"AMADEUS","url":"https://clinicaltrials.gov/study/NCT04173533","created_at":"2021-01-18T20:21:37.079Z","updated_at":"2024-07-02T16:35:03.802Z","phase":"Phase 3","brief_title":"Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT","source_id_and_acronym":"NCT04173533 - AMADEUS","lead_sponsor":"University of Birmingham","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 326","initiation":"Initiation: 06/14/2019","start_date":" 06/14/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-14"},{"id":"820e22ed-50fe-40f0-aa7c-051ded02330b","acronym":"CA209-117","url":"https://clinicaltrials.gov/study/NCT01928576","created_at":"2021-01-18T08:42:53.521Z","updated_at":"2025-02-25T14:34:17.894Z","phase":"Phase 2","brief_title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","source_id_and_acronym":"NCT01928576 - CA209-117","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/06/2013","start_date":" 11/06/2013","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-05-03"},{"id":"1ae89bb9-e654-4cae-adf5-e98fed55013d","acronym":"OGILAR","url":"https://clinicaltrials.gov/study/NCT06022003","created_at":"2023-09-01T17:11:43.343Z","updated_at":"2024-07-02T16:35:20.705Z","phase":"Phase 2","brief_title":"Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT06022003 - OGILAR","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/13/2024","start_date":" 01/13/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-02-06"},{"id":"b895ed07-c362-45fa-bccf-f3e71d5230b3","acronym":"NCI-2021-13436","url":"https://clinicaltrials.gov/study/NCT05162976","created_at":"2021-12-20T16:53:56.223Z","updated_at":"2024-07-02T16:35:24.788Z","phase":"Phase 1","brief_title":"CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed","source_id_and_acronym":"NCT05162976 - NCI-2021-13436","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/03/2022","start_date":" 01/03/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-01-01"},{"id":"b75c8e0c-7a34-42e8-acb6-f56117fba765","acronym":"","url":"https://clinicaltrials.gov/study/NCT03542266","created_at":"2022-11-13T19:37:00.102Z","updated_at":"2025-02-25T14:27:01.502Z","phase":"Phase 2","brief_title":"CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03542266","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 03/25/2020","primary_completion_date":" 03/25/2020","study_txt":" Completion: 07/25/2022","study_completion_date":" 07/25/2022","last_update_posted":"2023-08-22"},{"id":"aa427175-54cc-421c-9eb3-20e2eec8ad01","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703375","created_at":"2021-01-18T18:08:54.175Z","updated_at":"2024-07-02T16:36:00.520Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","source_id_and_acronym":"NCT03703375","lead_sponsor":"Celgene","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2022-11-14"},{"id":"a60a9098-0d9a-49ad-a3a2-71b073f9778a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02512172","created_at":"2021-01-29T07:10:33.387Z","updated_at":"2025-02-25T14:35:43.892Z","phase":"Phase 1","brief_title":"A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer","source_id_and_acronym":"NCT02512172","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • azacitidine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/19/2016","start_date":" 02/19/2016","primary_txt":" Primary completion: 11/20/2021","primary_completion_date":" 11/20/2021","study_txt":" Completion: 11/20/2021","study_completion_date":" 11/20/2021","last_update_posted":"2022-03-22"},{"id":"f73f9d34-6a69-444d-b459-edac7a10ed4d","acronym":"METADUR","url":"https://clinicaltrials.gov/study/NCT02811497","created_at":"2021-01-18T13:47:17.700Z","updated_at":"2024-07-02T16:36:32.530Z","phase":"Phase 2","brief_title":"Study of Azacitidine and Durvalumab in Advanced Solid Tumors","source_id_and_acronym":"NCT02811497 - METADUR","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • RAS wild-type • ER positive + HER-2 negative","tags":["EGFR • HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • RAS wild-type • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • azacitidine • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 11/08/2018","primary_completion_date":" 11/08/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2021-04-01"},{"id":"4adeed15-a02c-4426-90f2-4235120b6f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343536","created_at":"2021-01-18T11:08:23.071Z","updated_at":"2024-07-02T16:36:41.588Z","phase":"Phase 1","brief_title":"A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma","source_id_and_acronym":"NCT02343536","lead_sponsor":"Celgene","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 01/29/2020","primary_completion_date":" 01/29/2020","study_txt":" Completion: 01/29/2020","study_completion_date":" 01/29/2020","last_update_posted":"2020-08-28"},{"id":"4c6011fe-c4c1-44cd-84b3-1d40a184a9d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01545947","created_at":"2021-01-18T06:32:16.007Z","updated_at":"2024-07-02T16:36:53.837Z","phase":"Phase 1b","brief_title":"Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01545947","lead_sponsor":"Celgene","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • azacitidine • Onureg (azacitidine oral) • onatasertib (ATG-008)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 12/11/2014","primary_completion_date":" 12/11/2014","study_txt":" Completion: 12/11/2014","study_completion_date":" 12/11/2014","last_update_posted":"2019-11-12"},{"id":"7c0bee29-df1b-4e9b-b2b5-18c7da2b5b1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01478685","created_at":"2021-01-18T06:10:19.405Z","updated_at":"2024-07-02T16:36:53.840Z","phase":"Phase 1","brief_title":"A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT01478685","lead_sponsor":"Celgene","biomarkers":" DNMT1","pipe":"","alterations":" ","tags":["DNMT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 11/29/2011","start_date":" 11/29/2011","primary_txt":" Primary completion: 11/17/2015","primary_completion_date":" 11/17/2015","study_txt":" Completion: 11/17/2015","study_completion_date":" 11/17/2015","last_update_posted":"2019-11-12"},{"id":"63dda464-34e0-40e0-9bdc-ef3aacb2c2da","acronym":"","url":"https://clinicaltrials.gov/study/NCT01835587","created_at":"2021-01-18T08:10:20.767Z","updated_at":"2024-07-02T16:37:05.179Z","phase":"Phase 1/2","brief_title":"Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).","source_id_and_acronym":"NCT01835587","lead_sponsor":"Celgene","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 10/25/2013","start_date":" 10/25/2013","primary_txt":" Primary completion: 11/13/2016","primary_completion_date":" 11/13/2016","study_txt":" Completion: 05/26/2017","study_completion_date":" 05/26/2017","last_update_posted":"2018-11-20"},{"id":"3182f972-65df-4887-8ae2-016eef9a4809","acronym":"","url":"https://clinicaltrials.gov/study/NCT01846897","created_at":"2021-01-18T08:14:24.927Z","updated_at":"2024-07-02T16:37:21.110Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Epigenetic Priming in NSCLC Patients","source_id_and_acronym":"NCT01846897","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • pemetrexed • irinotecan • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-06-14"}]